Medacta Group SA · SIX:MOVE
Medacta Group SA — H1 2022 Earnings Presentation
11 slides from Medacta Group SA's earnings presentation, Jul 29, 2022
Slide 1: 1H 2022 Preliminary Unaudited Top-Line Figures
1H 2022 Preliminary Unaudited Top-Line Figures 29 July 2022
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Medacta Group SA ("Medacta" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Francesco Siccardi, CEO and Corrado Farsetta, CFO
FRANCESCO SICCARDI CORRADO FARSETTA Chief Executive Officer Chief Financial Officer 1H 2022 Preliminary Unaudited Top-Line Figures
Slide 4: 1H 2022 Highlights
1H 2022 Highlights 1H 2022 revenue increased to Euro 211.3 million, or 19.0% (14.6% at constant currency) from 1H 2021 Significant customer acquisition, salesforce expansion and product introduction drove the growth that was limited by pandemic restrictions and hospital staffing shortages in Aus
Slide 5: Revenue Bridge by Product Line
1H 2022 Revenue1 Bridge by Product Line 11.1% 16.1% 35.6% 16.0% 14.6% 19.0% 19.8; 9% (€m, %) 12.9; 6% (€m) 101.4; 48% 77.2; 37% 2 Hip Knee Extremities Spine Hip: growth driven by the AMIS® strategy, supported by further adoption of the Bikini technique, and the roll-out of new products Knee: goo
Slide 6: Revenue Bridge by Geographic Area
1H 2022 Revenue1 Bridge by Geographic Area 22.0% 10.8% 3.7% 31.8% 14.6% 19.0% 7.9; 4% (€m, %) (€m) 44.8; 21% 94.4; 45% 64.2; 30% Europe NA APAC ROW In 1H 2022 the geographic mix from prior period shows a shift from APAC to Europe mainly due to Covid-19 restrictions in Australia Europe: solid growt
Slide 7: 1H 2019-2022 True Growth beyond a Mere Recovery
1H 2019-2022 True Growth beyond a Mere Recovery 1H 2019-2022 Revenue1 Trend by Product Line 101.4 (€m) 88.4 82.9 77.2 68.9 REVENUE CAGR 63.4 53.7 1H 2019-2022 47.3 HIP 6.3% KNEE 11.9% 16.6 19.8 SPINE 21.9% 10.9 12.5 9.1 12.9 EXTREMITIES 44.5% 4.2 6.1 Total 10.9% 1H19 1H20 1H21 1H22 Total 151.6 134.8
Slide 8: NextAR AR Surgical Platform
NextAR™ AR Surgical Platform Following 1,000 NextAR™ surgeries performed worldwide in the limited market release phase, we reached 100 NextAR™ platforms in the market. This milestone was driven by the full market release of the NextAR™ shoulder application in May 2022 In June 2022, NextAR™ furth
Slide 9: 2022 Outlook
2022 Outlook Thanks to the positive business performance of the first semester, full-year revenue is expected in the top end of the original guidance range of Euro 400 million to Euro 414 million, at constant currency In light of the current macroeconomic and geopolitical situation and initiativ
Slide 10: Q&A
Q&A 1H 2022 Preliminary Unaudited Top-Line Figures
Slide 11: Medacta International
Adedacta International